FingerprintDive into the research topics of 'Adverse event profile differences between rituximab and ocrelizumab: Findings from the FDA Adverse Event Reporting Database'. Together they form a unique fingerprint.
- Sort by
Natalia Gonzalez Caldito, Afsaneh Shirani, Amber Salter, Olaf Stuve
Research output: Contribution to journal › Article › peer-review